Influenza (Including Avian Influenza and Swine Influenza)

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2000-2024.e6

  Treanor, John J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Avian influenza; Epidemic; Hemagglutinin; Inactivated influenza vaccine; Influenza A virus; Influenza B virus; Influenza C virus; Live attenuated influenza vaccine; Neuraminidase; Oseltamivir; Pandemic; Swine influenza; Zanamivir

Indexed keywords

EID: 84944552327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00167-3     Document Type: Chapter

References (429)

1. Hirsch A Handbook of Geographical and Historical Pathology 1883, New Sydenham Society, London. 2nd ed.
2. Crosby AW Epidemic and Peace, 1918 1976, Part IV, Greenwood Press, Westport, CT.
3. Smith W, Andrewes CH, Laidlaw PP A virus obtained from influenza patients. Lancet 1933, 2:66-68.
4. Francis T A new type of virus from epidemic influenza. Science 1940, 92:405-408.
5. Taylor RM A further note on 1233 ("influenza C") virus. Arch Gesamte Virusforsch 1951, 4:485-495.
6. Burnet FM Influenza virus on the developing egg, I. Changes associated with the development of an egg-passage strain of virus. Br J Exp Pathol 1936, 17:282-295.
7. Mogabgab WJ, Green IJ, Dierkhising OC Primary isolation and propagation of influenza virus in cultures of human embryonic renal tissue. Science 1954, 120:320-321.
8. Hirst GK The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science 1941, 94:22-23.
9. Francis T, Salk JE, Pearson HE, et al. Protective effect of vaccination against influenza A. Proc Soc Exp Biol Med 1944, 55:104-105.
10. Smorodintseff AA, Tushinsky MD, Drobyshevskaya AI, et al. Investigation of volunteers infected with the influenza virus. Am J Med Sci 1937, 194:159-170.
11. Kido H, Yokogoshi Y, Sakai K, et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar Clara cells: a possible activator of the viral fusion glycoprotein. J Biol Chem 1992, 267:13573-13579.
12. Kawaoka Y, Webster RG Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci U S A 1988, 85:324-328.
13. Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992, 11:2407-2414.
14. Horimoto T, Kawaoka Y Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994, 68:3120-3128.
15. Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci 2012, 109:4269-4274.
16. Zhu X, Yang H, Guo Z, et al. Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Proc Natl Acad Sci U S A 2012, 109:18903-18908.
17. Xu X, Lindstrom SE, Shaw MW, et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res 2004, 103:55-60.
18. Chen W, Calvo PA, Malide D, et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001, 7:1306-1312.
19. Jagger BW, Wise HM, Kash JC, et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 2012, 337:199-204.
20. Simonsen L, Clarke MJ, Williamson DW, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Pub Health 1997, 87:1944-1950.
21. Simonsen L, Taylor R, Viboud C, et al. US flu mortality estimates are based on solid science. BMJ 2006, 332:177-178.
22. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
23. Sullivan KM, Monto AS, Longini IM Estimates of the US health impact of influenza. Am J Pub Health 1993, 83:1712-1716.
24. Kavet J A perspective on the significance of pandemic influenza. Am J Pub Health 1977, 67:1063-1070.
25. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995, 333:889-893.
26. Neuzil KM, Hohlbein C, Zhu Y Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002, 156:986-991.
27. Keech M, Scott AJ, Ryan PJ The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998, 48:85-90.
28. Barker WH, Borisute H, Cox C A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 1998, 158:645-650.
29. Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 1991, 133:296-304.
30. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005, 353:2559-2567.
31. Ellis SE, Coffey CS, Mitchel EF, et al. Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. J Am Geriatr Soc 2003, 51:761-767.
32. Neuzil KM, Reed GW, Mitchel EF, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281:901-907.
33. Lin JC, Nichol KL Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
34. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010, 303:1517-1525.
35. Neuzil KM, Reed GW, Mitchel EF, et al. The impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998, 148:1094-1102.
36. Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010, 362:27-35.
37. Forbes RL, Wark PAB, Murphy VE, et al. Pregnant women have attenuated innate interferon responses to 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2012, 206:646-653.
38. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011, 52:301-312.
39. Kwong JC, Campitelli L, Rosella LC Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011, 53:413-421.
40. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
41. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children [see comments]. N Engl J Med 2000, 342:232-239.
42. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006, 118:2409-2417.
43. Silberry GK Complications of influenza infection in children. Pediatr Ann 2000, 29:683-690.
44. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
45. Glezen WP, Couch RB Interpandemic influenza in the Houston area, 1974-1976. N Engl J Med 1978, 298:587-593.
46. Ginsberg J, Mohebbi MH, Patel RS, et al. Detecting influenza epidemics using search engine query data. Nature 2009, 457:1012-1014.
47. Monto AS, Kioumehr F The Tecumseh study of respiratory illness, IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol 1975, 102:553-559.
48. Azziz Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis 2012, 206:838-846.
49. Schaffer FL, Soergel ME, Straube DC Survival of airborne influenza virus: effects of propagating host, relative humidity, and composition of spray fluids. Arch Virol 1976, 54:263-273.
50. Lowen AC, Mubareka S, Steel J, et al. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 2007, 3:e151.
51. Glezen WP, Couch RB, Six HR The influenza herald wave. Am J Epidemiol 1982, 116:589-598.
52. Buxton-Bridges C, Kuehnert MJ, Hall CB Transmission of influenza: implication for control in health care settings. J Infect Dis 2003, 37:1094-1101.
53. Bean B, Moore BM, Sterner B, et al. Survival of influenza viruses on environmental surfaces. J Infect Dis 1982, 146:47-51.
54. Boone SA, Gerba CP The occurrence of influenza A virus on household and day care center fomites. J Infect 2005, 51:103-109.
55. Blachere FM, Lindsley WG, Pearce TA, et al. Measurement of airborne influenza virus in a hospital emergency department. Clin Infect Dis 2009, 48:438-440.
56. Yang W, Elankumaran S, Marr L Concentrations and size distributions of airborne influenza A viruses measured indoors at a health center, a day-care center, and on airplanes. J R Soc Interface 2011, 8:1176-1184.
57. Alford RH, Kasel JA, Gerone PJ, et al. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 1966, 122:800-804.
58. Little JW, Douglas RG, Hall WJ, et al. Attenuated influenza produced by experimental intranasal inoculation. J Med Virol 1979, 3:177-188.
59. Andrewes C, Glover R Spread of infection from the respiratory tract of the ferret, I. Transmission of influenza A virus. Br J Exp Pathol 1941, 22:91-97.
60. Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airliner. J Epidemiol 1979, 110:1-6.
61. McLean R The effect of ultraviolet radiation upon the transmission of epidemic influenza in long-term hospital patients. Am Rev Respir Dis 1961, 83.
62. Drinka PJ, Krause P, Schilling M, et al. Report of an outbreak: nursing home architecture and influenza A attack rates. J Am Geriatr Soc 1996, 44:910-913.
63. Kaiser L, Henry D, Flack NP, et al. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000, 30:587-589.
64. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis 2007, 7:257-265.
65. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirators for preventing influenza among health care workers: a randomized trial. JAMA 2009, 302:1865-1871.
66. Cowling BJ, Chan KH, Fang V, et al. Facemasks and hand hygiene to prevent influenza transmission in households. Ann Intern Med 2009, 151:437-446.
67. World Health Organization Pandemic Influenza Risk Management: WHO Interim Guidance Available at, Accessed March 14, 2014. http://www.who.int/influenza/preparedness/pandemic/GIP_PandemicInfluenzaRiskManagementInterimGuidance:Jun2013.pdf.
68. Wilson IA, Cox NJ Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990, 8:737-771.
69. Webster RG, Laver WG Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 1980, 104:139-148.
70. Xu X, Cox NJ, Bender CA, et al. Genetic variation in the neuraminidase genes of influenza A (H3N2) viruses. Virology 1996, 224:175-183.
71. Rimmelzwaan GF, Boon AC, Voeten JT, et al. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 2004, 103:97-100.
72. Berkhoff EG, de Wit E, Geelhoed-Mieras MM, et al. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine 2006, 24:6594-6596.
73. Hay AJ, Gregory V, Douglas AR, et al. The evolution of human influenza viruses. Philos Trans R Soc Lond B 2001, 356:1861-1869.
74. Yamashita M, Krystal M, Fitch WM, et al. Influenza B virus evolution: co-circulating lineages and comparison of evolutionary patterns with those of influenza A and C viruses. Virology 1988, 163:112-122.
75. Smith DJ, Lapedes AS, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305:371-376.
76. Kilbourne ED Influenza 1987, Plenum Publishing, New York, NY.
77. Masurel N, Marine WM Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am J Epidemiol 1973, 97:44-49.
78. Kawaoka Y, Krauss S, Webster RG Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989, 63:4603-4608.
79. Taylor HR, Turner AJ A case report of fowl plague keratoconjunctivitis. Br J Opthalmol 1977, 61:86-88.
80. Kurtz J, Manvell RJ, Banks J Avian influenza virus isolated from a woman with conjunctivitis. Lancet 1996, 384:901-902.
81. Webster RG, Geraci J, Petursson G, et al. Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med 1981, 304:911.
82. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
83. Fouchier RAM, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004, 101:1356-1361.
84. Meijer A, Bosman A, van de Kamp EE, et al. Measurement of antibodies to avian influenza virus A (H7N7) in humans by hemagglutination inhibition test. J Virol Meth 2006, 132:113-120.
85. Hirst M, Astell CR, Griffith M, et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 2004, 10:2192-2195.
86. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 2004, 10:2196-2199.
87. Nguyen Van Tam J, Nair P, Acheson P, et al. Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill 2006, 11.
88. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368:2277-2285.
89. Ai J, Huang Y, Xu K, et al. Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu province, China, 2013. Euro Surveill 2013, 18:20510.
90. Skowronski DM, Janjua NZ, Kwindt TL, et al. Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013. Euro Surveill 2013, 18:20465.
91. Bai T, Zhou J, Shu Y Serologic study for influenza A (H7N9) among high-risk groups in China. N Engl J Med 2013, 368:2339-2340.
92. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999, 354:916-917.
93. Guo YJ, Krauss S, Senne DA, et al. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology 2000, 267:279-288.
94. Claas ECJ, Osterhous ADME, van Beek R, et al. Human influenza A H5N1 related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
95. World Health Organization Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec 2005, 81:249-257.
96. World Health Organization Avian influenza A (H5N1) infection in humans. N Engl J Med 2005, 353:1374-1385.
97. VanKerkhove MD, Mumford E, Mounts AW, et al. Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review. PLoS One 2011, 6.
98. Keawcharoen J, Oraveerakul K, Kuiken T, et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004, 10:2189-2191.
99. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999, 180:505-508.
100. Olsen SJ, Ungchusak K, Sovann T, et al. Family clustering of avian influenza A (H5N1). Emerg Infect Dis 2005, 11:1799-1801.
101. Butler D Pandemic "dry run" is cause for concern. Nature 2006, 441:554-555.
102. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005, 352:333-340.
103. Neumann G, Chen H, Gao GF, et al. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 2010, 20:51-61.
104. Uyeki TM Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009, 49:279-290.
105. de Jong MD, Cam BV, Qui PT, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005, 352:686-691.
106. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A(H5N1), Thailand 2004. Emerg Infect Dis 2005, 11:201-209.
107. To K, Paul KS, Chan K-F, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001, 63:242-246.
108. Beare AS, Webster RG Replication of avian influenza viruses in humans. Arch Virol 1991, 119:37-42.
109. Naffakh N, Tomoiu A, Rameix-Welti MA, et al. Host restriction of avian influenza viruses at the level of the ribonucleoproteins. Annu Rev Microbiol 2008, 62:403-424.
110. Murphy BR, Buckler-White AJ, London WT, et al. Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses. J Infect Dis 1984, 150:841-850.
111. Bean WJ, Schell M, Katz J, et al. Evolution of the H3 hemagglutinin from human and nonhuman hosts. J Virol 1992, 66:1129-1138.
112. Ito T, Couceiro JN, Kelm S, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998, 72:7367-7373.
113. Scholtissek C, Stech J, Krauss S, et al. Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses. J Virol 2002, 76:1781-1786.
114. Taubenberger JK, Reid AH, Krafft AE, et al. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997, 275:1793-1796.
115. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486:420-428.
116. Herfst S, Schrauwen EJA, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336:1534-1541.
117. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012, 336:1541-1547.
118. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
119. Olsen CW The emergence of novel swine influenza viruses in North America. Virus Res 2002, 85:199-210.
120. Vincent AL, Ma W, Lager KM, et al. Swine influenza viruses: a North American perspective. Adv Virus Res 2008, 72:127-154.
121. Newman AP, Reisdorf E, Beinemann J, et al. Human case of swine influenza A (H1N1) triple reassortant virus infection, Wisconsin. Emerg Infect Dis 2008, 14:1470-1478.
122. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009, 360:2616-2625.
123. Chou Y-Y, Albrecht RA, Pica N, et al. The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J Virol 2011, 85:11235-11241.
124. Lindstrom S, Garten R, Balish A, et al. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 2012, 18:834-837.
125. Centers for Disease Control and Prevention Update: Influenza activity-United States and worldwide, May 20-September 22, 2012. MMWR Morb Mortal Wkly Rep 2012, 61:785-789.
126. Wong KK, Greenbaum A, Moll ME, et al. Outbreak of influenza A (H3N2) variant virus infection among attendees of an agricultural fair, Pennsylvania, USA, 2011. Emerg Infect Dis 2012, 18:1937-1944.
127. Skowronski DM, Janjua NZ, de Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012, 206:1852-1861.
128. Sanz-Esquerro JJ, De La Luna S, Ortin J, et al. Individual expression of the influenza virus PA protein induces degradation of coexpressed proteins. J Virol 1995, 69:2420-2426.
129. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, et al. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol 1994, 68:3667-3673.
130. Mori I, Komatsu T, Takeuchi K, et al. In vivo induction of apoptosis by influenza virus. J Gen Virol 1995, 76:2869-2873.
131. Takizawa T, Fukuda R, Miyawaki T, et al. Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon. Virology 1995, 209:288-296.
132. Jordan WS, Badger GF, Dingle JH A study of illness in a group of Cleveland families, XVI. The epidemiology of influenza 1948-1953. Am J Hyg 1958, 68:169-189.
133. Larson HE, Parry RP, Tyrrell DAJ Impaired polymorphonuclear leucocyte chemotaxis after influenza virus infection. Br J Dis Chest 1980, 74:56-62.
134. Roberts NJ, Steigbigel RT Effect of in vitro virus infection on response of human monocytes and lymphocytes to mitogen stimulation. J Immunol 1978, 121:1052-1058.
135. Cooper JA, Carcelen R, Culbreth R Effects of influenza A nucleoprotein on polymorphonuclear neutrophil function. J Infect Dis 1996, 173:279-284.
136. Cooper JA, Culbreth RR Characterization of a neutrophil inhibitor peptide harvested from human bronchiolar lavage: homology to influenza A nucleoprotein. Am J Respir Cell Mol Biol 1996, 15:207-215.
137. Abramson JS, Wheeler JG, Parce JW, et al. Suppression of endocytosis in neutrophils by influenza A virus in vitro. J Infect Dis 1986, 154:456-463.
138. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J Clin Invest 1998, 101:643-649.
139. Lau LL, Ip DK, Nishiura H, et al. Heterogeneity in viral shedding among individuals with medically attended influenza A virus infection. J Infect Dis 2013, 207:1281-1285.
140. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004, 363:617-619.
141. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12:1203-1207.
142. Martin CM, Kunin CM, Gottlieb LS, et al. Asian influenza A in Boston, 1957-1958. Arch Intern Med 1959, 103:516-531.
143. Walsh JJ, Dietlein LF, Low FN, et al. Bronchotracheal response in human influenza. Arch Intern Med 1961, 108:376-388.
144. Guarner J, Shieh WJ, Dawson J, et al. Immunohistochemical and in situ hybridization studies of influenza A virus infection in human lungs. Am J Clin Pathol 2000, 114:227-233.
145. Oseasohn R, Adelson L, Kaji M Clinicopathologic study of thirty-three fatal cases of Asian influenza. N Engl J Med 1959, 11:509-518.
146. Little JW, Hall WJ, Douglas RG, et al. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis 1978, 118:295-303.
147. Hall WJ, Douglas RG, Hyde RW, et al. Pulmonary mechanics after uncomplicated influenza A infection. Am Rev Respir Dis 1976, 113:141-147.
148. Horner GJ, Gray FD Effect of uncomplicated, presumptive influenza on the diffusing capacity of the lung. Am Rev Respir Dis 1973, 108:866-869.
149. Johanson WGJ, Pierce AK, Sanford JP Pulmonary function in uncomplicated influenza. Am Rev Respir Dis 1969, 100:141-146.
150. 1 in asthmatic children. Chest 1991, 100:1235-1238.
151. Smith CB, Kanner RE, Goldern CA, et al. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980, 141:271-279.
152. Utell MJ, Aquilina AT, Hall WJ, et al. Development of airway reactivity to nitrates in subjects with influenza. Am Rev Respir Dis 1980, 121:233-241.
153. Louria DB, Blumenfeld HL, Ellis JT, et al. Studies on influenza in the pandemic of 1957-1958, II. Pulmonary complications of influenza. J Clin Invest 1959, 38:213-265.
154. Yelandi AV, Colby TV Pathologic features of lung biopsy specimens from influenza pneumonia cases. Hum Pathol 1994, 25:47-53.
155. Levandowski RA, Gerrity TR, Garrard CS Modifications of lung clearance mechanisms by acute influenza A infection. J Lab Clin Med 1985, 106:428-432.
156. Pittet LA, Hall-Stoodley L, Rutkowski MR, et al. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumonia. Am J Respir Cell Mol Biol 2010, 42:450-460.
157. Li W, Moltedo B, Moran TM Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of T cells. J Virol 2012, 86:12304-12312.
158. Tian X, Xu F, Lung WY, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One 2012, 7.
159. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004, 172:7603-7609.
160. Sun K, Metzger DW Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008, 14:558-564.
161. Small CL, Shaler CR, McCormick S, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 2010, 184:2048-2056.
162. Raftogiannis M, Antonopoulou A, Baziaka F, et al. Indication for a role of regulatory T cells for the advent of influenza A (H1N1)-related pneumonia. Clin Exp Immunol 2010, 161:576-583.
163. Epstein SL Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006, 193:49-53.
164. Black RA, Rota PA, Gorodkova N, et al. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993, 74:143-146.
165. Murphy BR, Kasel JA, Chanock RM Association of serum antineuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
166. Virelizier J-L Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 1975, 115:434-439.
167. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30:1081-1085.
168. Stephenson I, Das RG, Wood JM, et al. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25:4056-4063.
169. Kashyap AK, Steel J, Oner AF, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008, 105:5986-5991.
170. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208:181-193.
171. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
172. Ekiert DC, Friesen RHE, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850.
173. Pica N, Palese P Towards a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
174. Webster RG, Reay PA, Laver WG Protection against lethal influenza with neuraminidase. Virology 1988, 164:230-237.
175. Schulman JL, Khakpour M, Kilbourne ED Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2:778-786.
176. Schulman JL, Khakpour M, Kilbourne ED Protective effects of hemagglutinin and neuraminidase antigens on influenza virus: distinctiveness of hemagglutinin antigens of Hong Kong-68 virus. J Virol 1968, 2:778.
177. Monto AS, Kendal AP Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973, 7804:623-625.
178. Clements ML, Betts RF, Tierney EL, et al. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986, 23:73-76.
179. Johansson BE, Grajower B, Kilbourne ED Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11:1037-1039.
180. Treanor JJ, Tierney EL, Zebedee SL, et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64:1375-1377.
181. Jegerlehner A, Schmitz N, Storni T, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
182. Carragher DM, Kaminski DA, Moquin A, et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181:4168-4176.
183. Wagner DK, Clements ML, Reimer CB, et al. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol 1987, 25:559-562.
184. Murphy BR, Clements ML The systemic and mucosal immune response of humans to influenza A virus. Curr Topics Microbiol Immunol 1989, 146:107-116.
185. Renegar KB, Small PAJ Passive transfer of local immunity to influenza virus by IgA antibody. J Immunol 1991, 146:1972-1978.
186. Liew FY, Russell SM, Appleyard G, et al. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell activity. Eur J Immunol 1984, 14:409-413.
187. Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24:157-160.
188. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
189. Treanor J, Wright PF Immune correlates of protection against influenza in the human challenge model. Dev Biol 2003, 115:97-104.
190. + T-cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol 2011, 85:12057-12061.
191. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza-specific effector and memory B cell responses to immunization of children and adults with live attenuated or inactivated influenza vaccines. J Virol 2007, 81:215-228.
192. + T cells after influenza vaccination using MHC class I peptide tetramers. Scand J Immunol 2008, 67:86-94.
193. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009, 27:2418-2425.
194. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309:13-17.
195. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280.
196. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
197. Howard JB Influenza A2 virus as a cause of croup requiring tracheostomy. J Pediatr 1972, 81:1148-1150.
198. Glezen WP, Paredes A, Taber LH Influenza in children: relationship to other respiratory agents. JAMA 1980, 243:1345-1349.
199. Schwarzmann SW, Adler JL, Sullivan RFJ, et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971, 127:1037-1041.
200. Bisno AL, Griffin JP, VanEpps KA Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic. Am J Med Sci 1971, 261:251-274.
201. Centers for Disease Control Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006. MMWR Morb Mortal Wkly Rep 2007, 56:325-339.
202. Ahn S, Kim WY, Kim SH, et al. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respir Viruses 2011, 5:398-403.
203. Piacentini E, Sanches B, Arauzo V, et al. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired pneumonia. J Crit Care 2011, 26:201-205.
204. Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. J Pediatr 1989, 115:33-39.
205. Whimbey E, Eling LS, Couch RB, et al. Influenza A virus infection among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994, 13:437-440.
206. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997, 24:1095-1099.
207. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenza A viruses by immuno-deficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995, 172:1352-1355.
208. Evans KM, Kline MW Prolonged influenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995, 14:332-334.
209. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998, 178:1257-1262.
210. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006, 193:760-764.
211. Monto AS, Ross HW The Tecumseh study of respiratory illness, X. Relation of acute infections to smoking, lung function, and chronic symptoms. Am J Epidemiol 1978, 107:57-64.
212. Ferson MJ, Morton JR, Robertson PW Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health 1991, 27:308-311.
213. Crum-Cianflone NF Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 2008, 21:473-494.
214. Karjalainen J, Nieminen MS, Heikkila J Influenza A1 myocarditis in conscripts. Acta Med Scand 1980, 207:27-30.
215. Craver RD, Sorrells K, Gohd R Myocarditis with influenza B infection. Pediatr Infect Dis J 1997, 16:629-630.
216. MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenza like illness. JAMA 1987, 257:1053-1058.
217. Sperber SJ, Francis JB Toxic shock during an influenza outbreak. JAMA 1987, 257:1086-1089.
218. Kashiwada T, Kikuchi K, Abe S, et al. Staphylococcal enterotoxin B toxic shock syndrome induced by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Intern Med 2012, 51:3085-3088.
219. Edelen JS, Bender TR, Chin TDY Encephalopathy and pericarditis during an outbreak of influenza. Am J Epidemiol 1974, 100:79-83.
220. Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000, 31:1166-1169.
221. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000, 160:3243-3247.
222. Zambon M, Hays J, Webster A, et al. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med 2001, 161:2116-2122.
223. Walsh EE, Cox C, Falsey AR Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002, 50:1498-1503.
224. Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen FLU A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003, 41:3487-3493.
225. Falsey AR Noninfluenza respiratory virus infection in long-term care facilities. Infect Control Hosp Epidemiol 1991, 12:602-608.
226. Drinka PJ, Gravenstein S, Krause P, et al. Non-influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc 1999, 47:1087-1093.
227. Covalciuc KA, Webb KH, Carlson CA Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods. J Clin Microbiol 1999, 37:3971-3974.
228. Ryan-Pourier KA, Katz JM, Webster RG, Kawaoka Y Application of Directigen FLU-A for the detection of influenza A virus in human and non-human specimens. J Clin Microbiol 1992, 30:1072-1075.
229. Coiras MT, Perez-Brena P, Garcia ML, et al. Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in clinical samples by multiplex reverse transcription nested-PCR assay. J Med Virol 2003, 69:132-144.
230. Kimball AM, Foy HM, Cooney MK, et al. Isolation of respiratory syncytial and influenza viruses from the sputum of patients hospitalized with pneumonia. J Infect Dis 1983, 147:181-184.
231. Newton DW, Mellen CF, Baxter BD, et al. Practical and sensitive screening strategy for detection of influenza virus. J Clin Microbiol 2002, 40:4353-4356.
232. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management. Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1003-1032.
233. Bui M, Whittaker G, Helenius A Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996, 70:8391-8401.
234. Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986, 146:1751-1756.
235. Speeg KV, Leighton JA, Maldonado AL Case report: toxic delirium in a patient taking amantadine and trimethoprim-sulfamethoxazole. Am J Med Sci 1989, 298:410-412.
236. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A in humans. N Engl J Med 1982, 307:580-584.
237. Van Voris LP, Betts RF, Hayden FG, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981, 245:1128-1131.
238. Hayden FG, Monto AS Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986, 29:339-341.
239. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987, 80:275-282.
240. Thompson J, Fleet W, Lawrence E, et al. A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Virol 1987, 21:249-255.
241. Shiraishi K, Mitamura K, Sakai-Tagawa Y, et al. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003, 188:57-61.
242. Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985, 4:3021-3024.
243. Boivin G, Goyette N, Bernatchez H Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002, 34:E23-E25.
244. Bright RA, Medina M-J, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
245. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
246. Mitnaul LJ, Castrucci MR, Murti KG, et al. The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication. J Virol 1996, 70:873-879.
247. Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665-12667.
248. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999, 43:1616-1620.
249. Gravenstein S, Johnson SL, Loeschel E, et al. Zanamivir: a review of clinical safety in individuals at high-risk of developing influenza related complications. Drug Safety 2001, 24:1113-1125.
250. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999, 282:1240-1246.
251. Walker JB, Hussey EK, Treanor JJ, et al. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 1997, 176:1417-1422.
252. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized, controlled trial. JAMA 2000, 283:1016-1024.
253. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000, 355:1845-1850.
254. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997, 337:874-880.
255. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998, 352:1877-1881.
256. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20:127-133.
257. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000, 19:410-417.
258. McClellan K, Perry CM Oseltamivir: a review of its use in influenza. Drugs 2001, 61:263-283.
259. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001, 161:212-217.
260. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
261. Hernan MA, Lipsitch M Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011, 53:277-279.
262. Hiba V, Chowers M, Levi-Vinograd I, et al. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011, 66:1150-1155.
263. Rodriguez A, Diaz E, Martin-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011, 66:1140-1149.
264. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patiets with influenza A (H1N1)pdm09. Clin Infect Dis 2012, 55:1198-1204.
265. Piedra PA, Schulman KL, Blumentals WA Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009, 124:170-178.
266. Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996, 70:1818-1827.
267. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-neu5ac2en. J Virol 1997, 71:3385-3390.
268. Moscona A Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005, 353:2633-2636.
269. Blick TJ, Sahasrabudhe A, McDonald M, et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-neu5ac2en. Virology 1998, 246:95-103.
270. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
271. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002, 55:307-317.
272. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002, 54:79-88.
273. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002, 54:99-111.
274. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004, 190:1627-1630.
275. Seibert CW, Rhahmat S, Krammer F, et al. Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance. J Virol 2012, 86:5386-5389.
276. Dharan JN, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
277. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013, 56:1197-1205.
278. Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H2758Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012, 206:148-157.
279. Barrosa L, Treanor J, Gubareva L, et al. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomised, controlled trials for prophylaxis and treatment. Antivir Ther 2005, 10:901.
280. Lee CM, Weight AK, Haldar J, et al. Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection. Proc Natl Acad Sci U S A 2012, 109:20385-20390.
281. Kilbourne ED, Schulman JL, Schild GC, et al. Correlated studies of a recombinant influenza-virus vaccine, I. Derivation and characterization of virus and vaccine. J Infect Dis 1971, 124:449-462.
282. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51:997-1004.
283. Treanor JJ, El Sahly HM, King JC, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29:7733-7739.
284. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children-a population-based study. Arch Pediatr Adolesc Med 2004, 158:1031-1036.
285. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994, 272:1956-1961.
286. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med 1996, 156:1546-1550.
287. Wright PF, Thompson J, Vaughn WT, et al. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977, 136:S731-S741.
288. Gross PA, Ennis FA, Gaerlan PF, et al. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977, 136:623-632.
289. Centers for Disease Control and Prevention Update: Recommendations of the Advisory Committee on Immunization Practices regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. MMWR Morb Mortal Wkly Rep 2010, 59:989-992.
290. Maraskovsky E, Rockman S, Dyson A, et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine 2012, 30:7400-7406.
291. Chung EY, Huang L, Schneider L Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010, 125:e1024-e1030.
292. Centers for Disease Control and Prevention Prevention and Control of Influenza with Vaccines: Recommendations fo the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2011, 60:1128-1132.
293. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110:105-123.
294. Lasky T, Tarracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339:1797-1802.
295. Scheifele DW, Dubal B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis 2003, 36:850-857.
296. Tamma PD, Sult KS, del Rio D, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009, 201:547-553.
297. Wright PF, Cherry JD, Foy HM, et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children-a multicentered evaluation of dosage and toxicity. Rev Infect Dis 1983, 5:758-764.
298. Levandowski RA, Regnery HL, Staton E, et al. Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics 1991, 88:1031-1036.
299. Lerman SJ, Wright PJ, Patil KD Antibody decline in children following A/New Jersey/76 influenza virus immunization. J Pediatr 1980, 96:271-274.
300. Cate TR, Rayford Y, Nino D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2078.
301. Zahradnik JM, Kasel JA, Martin RR, et al. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol 1983, 11:277-285.
302. Bokstad KA, Eriksson J-C, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002, 185:878-884.
303. Keitel WA, Couch RB, Cate TR, et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994, 32:2468-2473.
304. Englund JA, Walter EB, Fairchok MP, et al. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005, 115:1039-1047.
305. + T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 2003, 171:3163-3169.
306. Nayak JL, Fitzgerald T, Richards KA, et al. CD4 T-cell expansion predicts neutralizing antibody responses to monovalent inactivated pandemic H1N1 influenza vaccine. J Infect Dis 2013, 207:297-305.
307. Zeman AM, Holmes TH, Stamatis S, et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007, 26:107-115.
308. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
309. Bucasas KL, Franco LM, Shaw CA, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011, 203:921-929.
310. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
311. Falsey AR, Treanor JJ, Tornieporth N, et al. Superior immunogenicity of high dose influenza vaccine compared with standard influenza vaccine in adults >65 years of age: a randomized double-blind controlled phase 3 trial. J Infect Dis 2008, 200:172-180.
312. Duchini A, Goss JA, Karpen S, et al. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003, 16:357-364.
313. Nelson KE, Clements ML, Miotti P, et al. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988, 109:383-388.
314. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000, 18:3040-3049.
315. Kubiet MA, Gonzalez-Rothi RJ, Cottey R, et al. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996, 110:367-370.
316. Park CL, Frank AL, Sullivan M, et al. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996, 98:196-200.
317. Petrie JG, Ohmit SE, Johnson E, et al. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
318. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169:68-76.
319. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial [see comments]. JAMA 2000, 284:1655-1663.
320. Osterholm MT, Kelley NS, Sommer A, et al. Influenza vaccine efficacy and effectiveness: a new look at the evidence. Lancet Infect Dis 2012, 12:36-44.
321. Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430-433.
322. Mahdi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficiency virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011, 52:128-137.
323. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003, 290:1608-1616.
324. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
325. Gross PA, Quinnan GV, Rodstein M, et al. Association of influenza immunization with reduction in mortality in an elderly population: a prospective study. Arch Intern Med 1988, 148:562-565.
326. Nichol KL, Nordin J, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.
327. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993, 270:1956-1961.
328. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003, 348:1322-1332.
329. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006, 35:345-352.
330. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006, 35:337-344.
331. Orenstein EW, de Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007, 36:623-631.
332. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccine in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012, 55:951-959.
333. Skowronski DM, Janjua NZ, de Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012, 55:332-342.
334. Talbot HK, Griffin MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011, 203:500-508.
335. Kelly H, Jacoby P, Dixon G, et al. Vaccine effectiveness against laboratory-confirmed influenza in healthy young children. Pediatr Infect Dis J 2011, 30:107-111.
336. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1555-1564.
337. Benowitz I, Esposito DB, Gracey KD, et al. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010, 51:1355-1361.
338. Francis TJ Vaccination against influenza. Bull World Health Organ 1953, 8:725-741.
339. Perkins FT Experience in the United Kingdom with oil adjuvant influenza vaccines. Ann Allergy 1972, 30:288-291.
340. Weibel RE, McLean A, Woodhour AF, et al. Ten-year follow-up study for safety of adjuvant 65 influenza vaccine in man. Proc Soc Exp Biol Med 1973, 143:1053-1056.
341. Podda A The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
342. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7:e33536.
343. Miller E, Andrews NJ, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:F794.
344. Szakacs A, Darin N, Hallbook T Increased childhood incidence of narcolepsy in western Sweden after H1N1 vaccination. Neurology 2013, 80:1315-1321.
345. Dauvilliers Y, Arnulf I, Mignot E Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
346. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012, 7:e33723.
347. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011, 70:410-417.
348. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31:1246-1254.
349. Tsai TF, Crucitti A, Nacci P, et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43:702-706.
350. De la Herrán-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013, 5:216ra176.
351. Maassab HF Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 1969, 102:728-732.
352. Murphy BR, Coelingh K Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
353. Herlocher LM, Clavo AC, Maasab HF Sequence com-parisons of the A/AA/6/60 influenza viruses: mutations which may contribute to attenuation. Virus Res 1996, 42:11-25.
354. Snyder MH, Betts RF, DeBorde D, et al. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 1988, 62:488-495.
355. Subbarao EK, Perkins M, Treanor JJ, et al. The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect. Virus Res 1992, 25:37-50.
356. Jin H, Lu B, Zhou H, et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306:18-24.
357. Chen Z, Aspelund A, Kemble G, et al. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist®). Virology 2006, 345:416-423.
358. Hoffman E, Mahmood K, Chen Z, et al. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 2005, 79:11014-11021.
359. Donabedian AM, DeBorde DC, Maassab HF Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microbiol Pathol 1987, 3:97-108.
360. Donabedian AM, DeBorde DC, Cook S, et al. A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology 1988, 163:444-451.
361. Buonagurio DA, O'Neill RE, Shutyak L, et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 2006, 347:296-306.
362. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
363. Redding G, Walker RE, Helssel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002, 21:44-48.
364. Gorse GJ, Belshe RB, Munn NJ Local and systemic antibody responses in high-risk adults given live attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988, 26:911-918.
365. Atmar RL, Bloom K, Keitel W, et al. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine 1990, 8:217-224.
366. Jackson LA, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999, 17:1905-1909.
367. King JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181:725-728.
368. King JC, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20:1124-1131.
369. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005, 26:494-500.
370. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006, 25:590-597.
371. Cha TA, Kao K, Zhao J, et al. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000, 38:839-845.
372. Beyer WEP, Palache AM, de Jong JC, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 2002, 20:1340-1353.
373. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999, 18:82-88.
374. Keitel WA, Couch RB, Quarles JM, et al. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993, 167:305-311.
375. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
376. Clements ML, Murphy BR Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986, 23:66-72.
377. Powers DC, Fries LF, Murphy BR, et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991, 29:498-505.
378. Powers DC, Murphy BR, Fries L, et al. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 1992, 40:163-167.
379. Brokstad KA, Eriksson J-C, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002, 185:878-885.
380. Cox RJ, Brokstad KA, Zuckerman MA, et al. An early humoral immune response in peripheral blood following parenteral influenza vaccination. Vaccine 1994, 12:993-999.
381. el-Madhun AS, Cox RJ, Soreide A, et al. Systemic and mucosal immune response in young children and adults after parenteral influenza vaccination. J Infect Dis 1998, 178:933-939.
382. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80:11756-11766.
383. He XS, Holmes TH, Mahmood K, et al. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 2008, 197:803-811.
384. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated cold-adapted trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 358:1405-1412.
385. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
386. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
387. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26:619-628.
388. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282:137-144.
389. DeVilliers PJT, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2010, 28:228-234.
390. Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992, 117:625-633.
391. Gorse GJ, O'Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003, 21:2133-2144.
392. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
393. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
394. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
395. Wang Z, Tobler S, Roayaei J, et al. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009, 301:945-953.
396. Monto AS, Davenport FM, Napier JA, et al. Modification of an outbreak of influenza in Tecumseh, Michigan, by vaccination of schoolchildren. J Infect Dis 1970, 122:16-25.
397. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010, 303:943-950.
398. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000, 284:1677-1682.
399. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344:889-896.
400. Kawai S, Nanri S, Ban E, et al. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis 2011, 53:130-136.
401. Centers for Disease Control and Prevention Influenza vaccination of health care personnel. MMWR Morb Mortal Wkly Rep 2006, 55:1-12.
402. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999, 281:908-913.
403. Salgado CD, Gianetta ET, Hayden FG, et al. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 2004, 25:923-928.
404. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997, 175:1-6.
405. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial [see comments]. Lancet 2000, 355:93-97.
406. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
407. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19:1732-1737.
408. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomized trial. Lancet 2006, 367:1657-1664.
409. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
410. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Nat Acad Sci U S A 2009, 106:7962-7967.
411. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3:85ra48.
412. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/04 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008, 198:635-641.
413. Zangwill KM, Treanor JJ, Campbell JD, et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008, 197:580-583.
414. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011, 203:666-673.
415. Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999, 179:1132-1138.
416. Suguitan AL, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets [see comment]. PLoS Med 2006, 3:1541-1555.
417. Jin H, Manetz S, Leininger J, et al. Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 2007, 25:8664-8672.
418. Chen H, Matsuoka Y, Swayne D, et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003, 21:4430-4436.
419. Chen H, Subbarao K, Swayne D, et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003, 21:1974-1979.
420. Karron R, Callahan K, Luke C, et al. Phase I evaluation of live attenuated H9N2 and H5N1 ca reassortant vaccines in healthy adults 2007, Presented at the Third WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials. Geneva, Switzerland, February 15-16.
421. Karron RA Clinical evaluation of live attenuated pandemic influenza virus vaccines 2008, Presented at the Fourth WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials. Geneva, Switzerland, February 14-15.
422. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999, 282:31-35.
423. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999, 341:1336-1346.
424. Peters PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001, 49:1025-1031.
425. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in hosehold contacts: a randomized controlled trial. JAMA 2001, 285:748-754.
426. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000, 343:1282-1289.
427. Mast EE, Harman MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A(H3N2). Am J Epidemiol 1991, 134:988-997.
428. Degelau J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992, 152:390-392.
429. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000, 21:700-704.